Menlo Park, Calif., December 15, 2014 – Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, is announcing that it completed its first draw down under the previously announced term loan facility with CRG LP (formerly known as Capital Royalty) and its affiliate funds ("CRG") for proceeds of $20 million before closing fees. The term loan facility gives the Company access to borrow up to $50 million, inclusive of the initial draw of $20 million.
About Nevro Corp.
Read More »
Headquartered in Menlo…
MENLO PARK, Calif., December 4, 2014 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has closed an expanded term loan facility with CRG and certain of its affiliate funds. The revised Term Loan Agreement provides an additional $10 million to the Company from CRG, which increases the aggregate principal loan amount to $45 million from the $35 million of outstanding principal provided for under the original agreement in July 2012. This revised term loan extends the maturity date of all debt to CRG from June…Read More »
Santa Rosa, CA, November 10, 2014 – TriVascular Technologies, Inc. (Nasdaq: TRIV) and CRG LP (formerly known as Capital Royalty) and its affiliate funds (“CRG”) today announced that they have amended and restated the term loan facility under which TriVascular previously borrowed $40 million in October 2012. In connection with this amendment, the company will increase its borrowings under the facility by $10 million upon closing of the transaction, which is anticipated to be completed by the end of the month, subject to customary closing conditions. Additionally, subject to the achievement of certain revenue milestones, TriVascular will have an option to…Read More »
MINNEAPOLIS – October 30, 2014 - Blue Belt Technologies, Inc. and CR Group (“CRG”) announced that they have closed a senior secured term loan for up to $40 million of capital. Blue Belt Technologies is an orthopedic surgical technology company with a focus on commercializing the next generation of robotic-assisted surgical tools. The company’s flagship product, the Navio® Surgical System, received CE Mark and FDA 510(k) clearance in 2012 and has been commercial in the U.S. since February, 2013. The Navio system provides robotic-assistance for partial knee replacement procedures through proprietary CT-free navigation software and a unique hand held computer controlled…Read More »
San Diego – October 9, 2014 – Astute Medical, Inc. and CRG today announced that Astute recently achieved a milestone under the terms of its existing term loan agreement with CRG. Under the term loan agreement, CRG will provide up to $30 million to support the commercialization of the NEPHROCHECK® Test System. An additional $10 million will become available to Astute upon the achievement of certain revenue milestones. Last month, Astute announced receipt of 510(k) clearance for the NEPHROCHECK® Test System from the United States Food and Drug Administration (FDA). The NEPHROCHECK® Test System is the first test for risk…Read More »
May 19, 2014 – Innovative Australasian pharmaceutical sales and development company, AFT Pharmaceuticals Ltd (AFT), has finalised an equity and structured debt funding package with Capital Royalty Partners (Houston, Boulder, New York) and equity funding with New Zealand-based Milford Asset Management (Auckland) though the Milford Active Growth Fund.
Capital Royalty and the Milford Active Growth Fund have collectively invested US$14M in equity in AFT, with Capital Royalty providing additional long-term capital of up to US$30M from a structured loan facility. AFT’s founders and only shareholders to date, Atkinson Family interests, will retain almost 90% ownership of the…
San Diego, CA – April 9, 2014 – Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) and Capital Royalty Partners II, L.P. and its affiliate funds (“Capital Royalty”) today announced that they have amended and restated the term loan facility under which the Company borrowed $30 million in January 2013. This amendment extends the maturity date under the Company’s term loan facility from December 31, 2017 to March 31, 2020. Under the terms of the restated agreement, the interest rate was reduced from 14.0 percent to 11.5 percent, and the interest only payment period was extended through March 31, 2018. In addition,…Read More »
Seattle, Washington – April 3, 2014 – NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a term loan agreement with Capital Royalty L.P. and certain of its affiliates. The agreement provides NanoString with up to $45 million of available borrowing capacity.
"Together with the capital we have raised through recent equity offerings, the agreement with Capital Royalty provides the funding we need to continue to pursue our business plan aggressively," stated Brad Gray, Chief Executive Officer of NanoString. “The optional…
BOULDER, Colorado – February 12, 2014 – Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix® with up to $20 million of capital.
“Capital Royalty’s financing structure has been uniquely tailored to suit our capital needs, especially during this growth phase of our company,” said David Brunel, Chief Executive Officer of Biodesix. “Their breadth of experience in the healthcare industry and deep knowledge of our business has convinced us that they are the right partner…